Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study;Skuteczność skojarzonego i wspomagającego leczenia temozolomidem u chorych z glejakiem wielopostaciowym. Wieloośrodkowe badanie z randomizacją

Neurologia i Neurochirurgia Polska

Volumn 47, Issue 2, 2013, Pages 101-108

  Szczepanek, Dariusz ^a   Marchel, Andrzej ^b   Moskał, Marek ^c   Krupa, Mariusz ^c   Kunert, Przemysław ^b   Trojanowski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Brain tumour; Glioblastoma; Radiotherapy; Temozolomide

Indexed keywords

CORTICOSTEROID; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RASH; REPEATED DRUG DOSE; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 84876888133     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2013.34398     Document Type: Article

References (24)

1. Curran W.J. Jr., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-710.
2. Stupp R., Hegi M.E., Neyns B., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-2718.
3. Frenel J.S., Botti M., Loussouarn D., et al. Prognostic and predictive factors for gliomas in adults. Bull Cancer 2009; 96: 357-367.
4. Stewart L.A. Chemotherapy in adult high grade glioma: a systematic review and metaanalysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
5. Nieder C., Mehta M.P., Jalali R. Combined radio-and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol) 2009; 21: 515-524.
6. Croteau D., Mikkelsen T. Adults with newly diagnosed highgrade gliomas. Curr Treat Options Oncol 2001; 2: 507-515.
7. Stupp R., Hegi M.E., Mason W.P., et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
8. Stupp R., Mason W., van den Bent M., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
9. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
10. Stupp R., Hegi M.E. Recent developments in the management of malignant glioma. In: Perry M.C. [ed.]. ASCO 2003 educational book. American Society of Clinical Oncology, Alexandria 2003, pp. 779-788.
11. Glas M., Happold C., Rieger J., et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27: 1257-1261.
12. Stupp R., Gander M., Leyvraz S., et al. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2: 552-560.
13. Kocher M., Frommolt P., Borberg S.K., et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008; 184: 572-579.
14. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363-4367.
15. Tolcher A.W., Gerson S.L., Denis L., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011.
16. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
17. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874.
18. Shapiro W.R. Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol 1992; 148: 428-434.
19. Stupp R., Dietrich P.-Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
20. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 2003; 5: 79-88.
21. Seiz M., Krafft U., Freyschlag C.F., et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: Experience of a single institution. J Cancer Res Clin Oncol 2010; 136: 1691-1695.
22. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O-6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-3857.
23. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997; 8: 92-97.
24. Wick W., Wick A., Schulz J.B., et al. Prevention of irradiationinduced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002; 62: 1915-1919.